Search results for Omburtamab

Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade, ProteoGenix, PX-TA1532

Description of Omburtamab Biosimilar - Anti-CD276, B7-H3, B7RP-2 mAb - Research Grade Introduction to Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb Omburtamab Biosimilar, also known as Anti-CD276, B7-H3, B7RP-2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancer. This biosimilar is designed to target the CD276 protein, also known as B7-H3 or B7RP-2, which is overexpressed in many types of cancer cells. In this article, we will explore the structure, activity, and potential applications of Omburtamab Biosimilar. Structure of Omburtamab Biosimilar Omburtamab Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to specifically target the CD276 protein. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of about 21 days. The binding site of Omburtamab Biosimilar is located on the Fc region of the antibody, which allows for interaction with immune cells and activation of immune responses. The variable regions of the antibody, also known as the antigen-binding sites, are responsible for binding to the CD276 protein on the surface of cancer cells. Activity of Omburtamab Biosimilar The main activity of Omburtamab Biosimilar is its ability to bind to the CD276 protein on the surface of cancer cells. This binding triggers a series of immune responses, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These responses result in the destruction of cancer cells and inhibition of tumor growth. In addition, Omburtamab Biosimilar has been shown to have a direct anti-tumor effect by inducing apoptosis, or programmed cell death, in cancer cells. This is achieved by blocking the signaling pathways involved in cancer cell survival and proliferation. Applications of Omburtamab Biosimilar Omburtamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including neuroblastoma, melanoma, and lung cancer. It has also been investigated for its potential to treat other diseases, such as autoimmune disorders and infectious diseases. In neuroblastoma, Omburtamab Biosimilar has shown to be effective in targeting and killing cancer cells, while sparing healthy cells. This makes it a potential treatment option for this aggressive form of childhood cancer. In melanoma, Omburtamab Biosimilar has been shown to enhance the anti-tumor effects of other therapies, such as chemotherapy and immune checkpoint inhibitors. This makes it a promising candidate for combination therapy in the treatment of this deadly form of skin cancer. In lung cancer, Omburtamab Biosimilar has shown to be effective in targeting cancer cells that have become resistant to chemotherapy. It has also been shown to enhance the activity of other targeted therapies, such as EGFR inhibitors. Conclusion In summary, Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade is a promising monoclonal antibody that has been designed to target the CD276 protein, which is overexpressed in many types of cancer cells. Its unique structure and activity make it a potential treatment option for various types of cancer, including neuroblastoma, melanoma, and lung cancer. Omburtamab Biosimilar is currently being evaluated in clinical trials and has the potential to improve the outcomes of cancer patients.

Omburtamab, Abbexa, abx831492

Omburtamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD276/B7-H3/B7RP-2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Omburtamab is a monoclonal antibody that targets the B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, former name: Burtomab) is a monoclonal antibody that is linked to a radioisotope and can bind to the B7-H3 antigen on the surface of neuroblastoma cells. It is injected directly into the cerebrospinal fluid to bypass the blood-brain barrier and accurately target neuroblastoma in the central nervous system to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain).

Omburtamab ELISA Kit, ProteoGenix, KPTX267

Description of Omburtamab ELISA Kit The Structure and Function of Omburtamab ELISA Kit: A Powerful Tool for Detecting and Studying Omburtamab Antibody The Basics of Omburtamab ELISA Kit Omburtamab ELISA Kit is a powerful and versatile tool used in the field of immunology for detecting and quantifying Omburtamab antibody in biological samples. This kit utilizes the enzyme-linked immunosorbent assay (ELISA) technique, which is a widely used method for detecting and measuring the presence of specific antibodies in a sample. The Structure of Omburtamab ELISA Kit The Omburtamab ELISA Kit is composed of several components including microtiter plates, Omburtamab antibody, enzyme-conjugated secondary antibody, substrate solution, and stop solution. The microtiter plates are coated with a specific antigen that binds to the Omburtamab antibody present in the sample. The enzyme-conjugated secondary antibody binds to the Omburtamab antibody, and the substrate solution produces a color change in the presence of the enzyme, which can be measured using a spectrophotometer. The Activity of Omburtamab ELISA Kit The Omburtamab ELISA Kit is a highly sensitive and specific tool for detecting and quantifying Omburtamab antibody in various biological samples. The kit is based on the principle of antigen-antibody interaction, where the Omburtamab antibody present in the sample binds to the specific antigen coated on the microtiter plate. The enzyme-conjugated secondary antibody then binds to the Omburtamab antibody, and the substrate solution produces a color change, which is directly proportional to the amount of Omburtamab antibody present in the sample. This color change can be measured using a spectrophotometer, providing a quantitative measurement of the Omburtamab antibody in the sample. The Application of Omburtamab ELISA Kit Omburtamab ELISA Kit has a wide range of applications in the field of immunology, particularly in the study of Omburtamab antibody. This kit can be used to detect and quantify Omburtamab antibody in various biological samples, including serum, plasma, and cell culture supernatant. It is also a useful tool for monitoring the levels of Omburtamab antibody in patients undergoing immunotherapy with Omburtamab, a monoclonal antibody used in the treatment of neuroblastoma. The Omburtamab ELISA Kit is also used in research studies to investigate the role of Omburtamab antibody in various diseases and conditions. This kit can help researchers understand the mechanism of action of Omburtamab and its potential therapeutic effects. Additionally, the Omburtamab ELISA Kit can be used to screen potential therapeutic agents that target Omburtamab antibody, aiding in the development of new treatments for diseases associated with Omburtamab. The Advantages of Omburtamab ELISA Kit The Omburtamab ELISA Kit offers several advantages over other methods of detecting and quantifying Omburtamab antibody. It is a simple, rapid, and cost-effective method that can be easily performed in a laboratory setting. The kit also has a high sensitivity and specificity, allowing for accurate and reliable results. Furthermore, the Omburtamab ELISA Kit can process a large number of samples simultaneously, making it a valuable tool for high-throughput studies. Conclusion Omburtamab ELISA Kit is a powerful and versatile tool for detecting and quantifying Omburtamab antibody in various biological samples. Its simple and efficient design, along with its high sensitivity and specificity, makes it a valuable tool for researchers and clinicians alike. With the increasing use of Omburtamab in immunotherapy, the

Omburtamab ELISA Kit, Abbexa, abx395156

Omburtamab ELISA Kit is a quantitative ELISA kit for detection of Omburtamab.

Omburtamab Biosimilar - Research Grade, ichor.bio, ICH5095

Detects human CD276

Research Grade Omburtamab (HV612026), abinScience, HV612026